Mr. Hinshaw is a greater than 30-year veteran of the biotechnology and pharmaceutical industries. Prior to joining Fore, he was the President and Chief Executive Officer of Axcella Therapeutics, a clinical-stage and publicly traded biopharmaceutical company developing novel therapies for complex diseases. Prior to Axcella, Mr. Hinshaw led all aspects of Novartis’ U.S. Oncology business, including products such as Tasigna®, Gleevec®, and Kymriah®, as well as the integration of the GSK oncology portfolio, including Tafinlar® and Mekinist®. He also played a key role on the Global Oncology Executive Committee, including leading crucial strategic programs to maximize the portfolio and develop the pipeline. Mr. Hinshaw has also led Corporate Social Responsibility programs including the Malaria Initiative and Arogya Parivar and was a member of BIO.
Earlier in his tenure at Novartis, Mr. Hinshaw held a number of leadership positions of increasing responsibility and expanding global scope, including Head of the NCE (Northern and Central Europe) Region for Novartis Oncology, GEM (Group Emerging Markets), Head of the Hematology Business Franchise, and Global Head of Infectious Disease and Transplantation (IDTI). Before joining Novartis, Mr. Hinshaw worked at the former Schering Plough Corporation where he held a series of commercial roles, including the Head of US Oncology. Mr. Hinshaw holds a B.S. in Molecular Biology from the University of Wisconsin.
